8-K: PepGen Receives UK Regulatory Clearance for Phase 2 DMD Trial

PepGen has received clearance from the UK's MHRA to begin a Phase 2 clinical trial for its PGN-EDO51 therapy for Duchenne Muscular Dystrophy.

Summary

• PepGen has announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has cleared its Clinical Trial Application (CTA) for the CONNECT2-EDO51 Phase 2 clinical trial.
• This trial will evaluate PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51-skipping.
• The CONNECT2-EDO51 trial is a multinational, randomized, double-blind, placebo-controlled study involving approximately 20 boys and young men.
• Participants will receive seven doses of PGN-EDO51 or a placebo over 24 weeks, with dose escalation from 5 mg/kg to 10 mg/kg and potentially higher.
• The trial will assess exon skipping, dystrophin production, and safety and tolerability, with muscle biopsies taken at baseline and week 25.
• PGN-EDO51 uses PepGen's Enhanced Delivery Oligonucleotide (EDO) technology to target the root cause of DMD by skipping exon 51.
• Preclinical studies showed PGN-EDO51 resulted in higher levels of exon 51 skipping compared to a competitor, potentially leading to higher dystrophin production.
• A Phase 1 study in healthy volunteers showed PGN-EDO51 had six times higher mean exon 51 skipping compared to a naked oligonucleotide.

Sentiment

Score: 8

Explanation: The document is positive due to the regulatory clearance and the potential for accelerated approval. The company's technology and preclinical results are also promising. However, there are inherent risks in clinical trials, which temper the overall sentiment.

Positives

• The clearance of the CTA by the UK MHRA is a significant step forward for the development of PGN-EDO51.
• The Phase 2 trial design includes a placebo-controlled group, which will provide robust data on the efficacy of PGN-EDO51.
• The potential for accelerated approval of PGN-EDO51 is a positive sign for the therapy's future.
• The EDO technology has shown promising results in preclinical and Phase 1 studies.
• The trial will assess key efficacy endpoints such as exon skipping and dystrophin production.

Negatives

• The trial involves a relatively small number of participants (approximately 20), which may limit the generalizability of the results.
• The trial is still in Phase 2, and there is no guarantee that it will be successful.
• The potential for dose escalation introduces some uncertainty regarding the safety and tolerability of higher doses.
• The company is dependent on third parties for manufacturing, research, and testing.

Risks

• There are risks associated with delays or failure to complete the clinical trial.
• Patient enrollment may be challenging.
• The interpretation of clinical and preclinical study results may be incorrect.
• The product candidate may not be safe or effective.
• Regulatory interactions may lead to delays or modifications to the development program.
• Unexpected increases in expenses could impact financial resources.
• The company is dependent on third parties for some aspects of product development.

Future Outlook

The company anticipates that the CONNECT2-EDO51 trial, along with data from the ongoing CONNECT1-EDO51 trial, could potentially support accelerated approval of PGN-EDO51, subject to alignment with regulators. The company also plans to continue developing its pipeline of oligonucleotide therapeutic candidates.

Management Comments

• James McArthur, Ph.D., President and CEO of PepGen, stated that they are excited to take the next step forward in the development of PGN-EDO51.
• He believes PGN-EDO51 is a potentially transformative investigational candidate for people living with DMD.
• He also expressed gratitude to continue working with the DMD community to develop this therapy.

Industry Context

This announcement is significant in the context of the broader industry trend of developing targeted therapies for rare genetic diseases. The focus on exon skipping and enhanced delivery technologies aligns with current research efforts to improve the efficacy of oligonucleotide therapies for DMD. The company is competing with other companies developing similar therapies.

Comparison to Industry Standards

• PepGen's PGN-EDO51 is being compared to other exon-skipping therapies for DMD, particularly those using peptide-conjugated oligonucleotides.
• The company claims that PGN-EDO51 has shown higher levels of exon 51 skipping in preclinical studies compared to a molecule structurally equivalent to the most clinically advanced peptide-conjugated oligonucleotide therapeutic candidate.
• PepGen also reports that PGN-EDO51 exhibited the highest level of exon 51 skipping in primate skeletal muscles, including the diaphragm, compared to other approved therapies or known development candidates based on publicly available data.
• In a Phase 1 study, PGN-EDO51 showed six times higher mean exon 51 skipping compared to a naked oligonucleotide, based on cross-trial comparisons of publicly available data.

Stakeholder Impact

• Shareholders may view this announcement positively due to the progress in clinical development.
• Patients with DMD and their families may be hopeful about the potential of PGN-EDO51.
• Employees of PepGen may be motivated by the progress of the company's lead candidate.
• The company's suppliers and partners may benefit from the continued development of PGN-EDO51.

Next Steps

• PepGen will initiate the CONNECT2-EDO51 Phase 2 clinical trial.
• The company will continue to evaluate safety and efficacy data from the trial.
• PepGen will continue to work with regulators to explore the potential for accelerated approval of PGN-EDO51.
• The company will continue to develop its pipeline of oligonucleotide therapeutic candidates.

Key Dates

Keywords

Duchenne Muscular Dystrophy, PGN-EDO51, Exon Skipping, Clinical Trial, MHRA, Oligonucleotide Therapy, EDO Technology, Phase 2, Neuromuscular Disease